Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
August 20, 2020 08:30 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on August 18, 2020 received notice from the Listing Qualifications Staff...
Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays
July 21, 2020 06:05 ET
|
Interpace Biosciences, Inc.
Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
Interpace Biosciences Announces First Quarter 2020 Financial and Business Results
June 25, 2020 16:59 ET
|
Interpace Biosciences, Inc.
First Quarter Net Revenue Improved Over 53% to $9.2 Million Launching COVID-19 Serology Testing Continues to Integrate Service Offerings and Streamline Costs Conference Call and Webcast Thursday...
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020
June 24, 2020 16:20 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m....
Interpace Biosciences Announces Contract with Lab Benefits Management Firm
April 27, 2020 06:55 ET
|
Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, April 27, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace...
Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results
April 22, 2020 16:05 ET
|
Interpace Biosciences, Inc.
Acquired Biopharma Business of Cancer Genetics in Second Half of 2019 Through Q1-2020 Raised $47 million from Two Top Private Equity FirmsProvides First Quarter 2020 Range of Revenues Expects to...
Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial Results on Wednesday, April 22, 2020
April 22, 2020 13:38 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, April 22, 2020 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company...
Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts
March 11, 2020 21:24 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross...
Interpace Diagnostics Announces Contract with BCBS of Massachusetts
March 10, 2020 06:55 ET
|
Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced...
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
March 02, 2020 06:55 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s...